Related Experiment Video
Updated: Jun 3, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Potassium-competitive acid blockers: Clinical pearls and practical insights
Hisham Wehbe1, Claire Beveridge2
1Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, OH.
None:
Potassium-competitive acid blockers (P-CABs) are a new class of acid-suppressing drugs; to date, only one of them (vonoprazan) has been approved for use in the United States. The authors of this article review how P-CABs (and vonoprazan in particular) differ from proton pump inhibitors (PPIs), evidence supporting their effectiveness, indications for vonoprazan, and ongoing and future studies.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Bronsted-Lowry Acids and Bases
Depolarizing Blockers: Pharmocokinetics
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
